about
Distinct evolutionary mechanisms for genomic imbalances in high-risk and low-risk neuroblastomasIntratumour diversity of chromosome copy numbers in neuroblastoma mediated by on-going chromosome loss from a polyploid stateLysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapyGeneration of trisomies in cancer cells by multipolar mitosis and incomplete cytokinesisArsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro.Increased health care utilization by survivors of childhood lymphoblastic leukemia is confined to those treated with cranial or total body irradiation: a case cohort studyNF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotypeOncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma.Deletions of 16q in Wilms tumors localize to blastemal-anaplastic cells and are associated with reduced expression of the IRXB renal tubulogenesis gene cluster.Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.Identification of BIRC6 as a novel intervention target for neuroblastoma therapy.Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours.Defective chromosome segregation and telomere dysfunction in aggressive Wilms' tumors.MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.Hypoxia-induced dedifferentiation in neuroblastoma cells.Activation of human telomerase reverse transcriptase through gene fusion in clear cell sarcoma of the kidney.Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.Arsenic trioxide and neuroblastoma cytotoxicity.ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.Haploidentical stem cell transplantation in two children with mucopolysaccharidosis VI: clinical and biochemical outcome.Severe gonadotoxic insult manifests early in young girls treated for Ewing sarcoma.Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research.The basic helix-loop-helix transcription factor dHAND, a marker gene for the developing human sympathetic nervous system, is expressed in both high- and low-stage neuroblastomas.snoRNPs Regulate Telomerase Activity in Neuroblastoma and Are Associated with Poor Prognosis.Venous thrombosis in children and adolescents with Hodgkin lymphoma in Sweden.Emergence of new ALK mutations at relapse of neuroblastoma.Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth.Alternative lengthening of telomeres--an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas.Genetic bottlenecks and the hazardous game of population reduction in cell line based research.The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells in vivo.mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma.Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN.Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma.Genetic heterogeneity in rhabdomyosarcoma revealed by SNP array analysis.Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53.Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer.High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.Absence of Epstein-Barr and cytomegalovirus infection in neuroblastoma cells by standard detection methodologies.
P50
Q21245646-9F2D554B-B3E3-452B-960D-8773A20BDEB2Q27334127-37856933-60A4-4F40-8D3A-75B6F7C9787EQ28235397-D4AB16BE-1E31-4C3F-BBDD-C977A04E8810Q30497558-5B99AC05-F3BC-44F1-8729-0EA0ABEE65E2Q31454789-9F3258F3-E3CC-4053-8281-DFA212B7EEFAQ33761036-F298E232-CA53-493E-B31E-B74C18C55220Q34031980-9BA14C6D-81D2-42A4-9311-88DE0D79A71CQ34068218-4F464C45-D994-45F6-9A1B-C4CCB5342200Q34210060-EEEDA083-4FD3-4ABF-B4AE-E54D03BA184DQ34254608-CFBAF43F-6BA8-4E81-BDFB-87E1F4FD08CFQ34257086-B3611BF5-E48D-4BAD-815E-14CF0A849645Q34334471-CF4B1A33-D06A-4CE5-8EA1-9644AA2CE652Q34438553-A74C8E90-11AD-48C3-B5D5-7D82FB3E14FAQ34714116-3C7B4E0C-E4CE-4AD9-99AB-E88D4CD001CDQ35043574-579BBE31-0239-4CF8-8250-1AFD1EB0F2E1Q35184973-31603548-6E6A-4AB4-A2F7-70517A405E4FQ35496976-4F1F73D5-5640-4303-AED7-FB30AE135552Q35965396-03C6D6FE-35A7-4989-9ECF-A61748708E4DQ36840797-9777A15D-9F50-4902-98D9-2544DB611DE2Q37154010-358EB13C-AC13-42CC-A75B-0D90231EA01AQ37154973-5DD106EB-66DD-431B-AF49-2EB818F56B29Q37726703-5872BCFA-1A57-46CA-8892-1BA43F941224Q37907460-7CCFBC10-305C-401E-9437-AA6F6017CB8EQ38461661-D982B776-7A34-4F62-A84B-555FDF261134Q38487500-63CCF2BC-E868-46F1-9982-635ECB086ACFQ38935468-1C931A7E-CD20-4CAA-B93C-44D1CAFA2E30Q38970741-AE12A119-0CBE-4689-8E62-C63C9F8927D9Q39390037-B3728F4E-7D88-4EF5-8154-B19A69AF049CQ39592676-AAF93A23-4CA5-40C9-80E2-E3B024E53EADQ39678430-38458733-62CF-48F8-B9D3-6634502C210DQ39895600-F73DD368-6712-43EB-BDF0-95BF179EC9E9Q39936326-40BF457C-095C-4400-864A-301C084ABF44Q40024162-CCF56ACD-18E1-4735-AD5B-E4968699820EQ40040010-562B0B97-AA45-4E6F-81D0-DD9F334EC913Q40083216-87EACC3B-A67F-4FFB-BAFA-1AF3195063EFQ40414512-5C9F039E-52A5-453C-81E0-0B504BD73F3BQ40558335-81D3C132-FF1E-4E89-9D4C-2EBBD431000CQ41520220-52FE3460-F453-47F3-9BFC-BD7BB5167A46Q43297419-C467329C-0CC0-4B2E-8F20-041A15AE7BEEQ43561288-0D74697A-2E67-4522-B2FA-EB061449792C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ingrid Øra
@ast
Ingrid Øra
@en
Ingrid Øra
@es
Ingrid Øra
@nl
Ingrid Øra
@sl
type
label
Ingrid Øra
@ast
Ingrid Øra
@en
Ingrid Øra
@es
Ingrid Øra
@nl
Ingrid Øra
@sl
altLabel
Ingrid Ora
@en
prefLabel
Ingrid Øra
@ast
Ingrid Øra
@en
Ingrid Øra
@es
Ingrid Øra
@nl
Ingrid Øra
@sl
P1053
J-2596-2013
P106
P1153
6602598751
P21
P31
P3829
P496
0000-0002-3931-4125
P6634
ingrid-øra-53ab0428